Vaxart Yönetim

Yönetim kriter kontrolleri 2/4

Vaxart CEO'su Steven Lo, Mar2024 tarihinde atandı, in görev süresi 1.17 yıldır. in toplam yıllık tazminatı $ 2.21M olup, şirket hissesi ve opsiyonları dahil olmak üzere 21.4% maaş ve 78.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.061% ine doğrudan sahiptir ve bu hisseler $ 64.09K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 3.8 yıldır.

Anahtar bilgiler

Steven Lo

İcra Kurulu Başkanı

US$2.2m

Toplam tazminat

CEO maaş yüzdesi	21.40%
CEO görev süresi	1.2yrs
CEO sahipliği	0.06%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

Lacklustre Performance Is Driving Vaxart, Inc.'s (NASDAQ:VXRT) 36% Price Drop

Feb 25

Revenues Not Telling The Story For Vaxart, Inc. (NASDAQ:VXRT) After Shares Rise 47%

Jan 04

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Nov 16

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Aug 20

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Jun 15

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Jul 20

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Jul 07

Vaxart: A Unique Vaccine Concern

Jun 14

CEO Tazminat Analizi

Steven Lo'un ücretlendirmesi Vaxart'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2025	n/a	n/a	-US$58m
Dec 31 2024	US$2m	US$474k	-US$67m

Tazminat ve Piyasa: Steven 'nin toplam tazminatı ($USD 2.21M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 645.80K ).

Tazminat ve Kazançlar: Steven şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Steven Lo (57 yo)

1.2yrs

Görev süresi

US$2,213,697

Tazminat

Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. From October 2019 to August 2022, Mr. Lo was the President, Chief Executive Officer and member of the board of direct...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Steven Lo	President	1.2yrs	US$2.21m	0.061% $ 64.1k
Sean Tucker	Senior VP & Chief Scientific Officer	15.3yrs	US$1.16m	0.12% $ 123.7k
James Cummings	Chief Medical Officer	3.8yrs	US$1.21m	0.095% $ 98.9k
Phillip Eric Lee	CFO, Principal Financial Officer & Principal Accounting Officer	2.4yrs	Veri yok	0.047% $ 48.9k
Raymond Stapleton	Chief Technology Officer	2.8yrs	Veri yok	Veri yok
Edward Berg	Senior VP & General Counsel	3.3yrs	Veri yok	0.077% $ 80.3k
Laurie Hastings	Senior Vice President of Human Resources	less than a year	Veri yok	Veri yok
Shaily Garg	Senior Vice President of Clinical Development & Project Management	5.2yrs	Veri yok	Veri yok
Rajesh Kapoor	Senior Vice President of Quality	4.3yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim: VXRT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Steven Lo	President	1.2yrs	US$2.21m	0.061% $ 64.1k
Harry Greenberg	Member of Scientific & Clinical Advisory Board	3.8yrs	Veri yok	Veri yok
Elaine Heron	Independent Director	2.8yrs	US$143.78k	0.0086% $ 9.0k
Michael Finney	Independent Chairman of the Board	7.3yrs	US$858.00k	0.29% $ 306.8k
Stanley Plotkin	Member of Scientific & Clinical Advisory Board	3.8yrs	Veri yok	Veri yok
Stefan Gravenstein	Member of Scientific & Clinical Advisory Board	3.8yrs	Veri yok	Veri yok
David Wheadon	Independent Director	4.1yrs	US$146.98k	0.0065% $ 6.7k
Robert Belshe	Member of Scientific & Clinical Advisory Board	3.8yrs	Veri yok	Veri yok
William Watson	Independent Director	2.8yrs	US$94.76k	0.025% $ 26.2k
Marion Pepper	Member of Scientific & Clinical Advisory Board	3.8yrs	Veri yok	Veri yok
Ralph Baric	Member of Scientific & Clinical Advisory Board	3.8yrs	Veri yok	Veri yok
Gregory Gray	Member of Scientific & Clinical Advisory Board	3.8yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: VXRT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/22 15:00
Gün Sonu Hisse Fiyatı	2025/05/22 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Vaxart, Inc. 4 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Mayank Mamtani	B. Riley Securities, Inc.
Roger Song	Jefferies LLC
Cheng Li	Oppenheimer & Co. Inc.

Vaxart Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Vaxart, Inc., Annual General Meeting, May 21, 2025

Vaxart, Inc. Announces Board and Committee Changes

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Vaxart, Inc. Announces CEO Changes

High number of new and inexperienced directors

Recent updates

New major risk - Share price stability

Consensus revenue estimates increase by 171%

First quarter 2025 earnings released: US$0.068 loss per share (vs US$0.14 loss in 1Q 2024)

Vaxart, Inc. Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2B Covid-19 Trial

New major risk - Revenue and earnings growth

Price target increased by 24% to US$6.00

Vaxart, Inc. to Report Q1, 2025 Results on May 13, 2025

Vaxart, Inc., Annual General Meeting, May 21, 2025

New minor risk - Market cap size

Consensus revenue estimates decrease by 77%, EPS upgraded

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

No longer forecast to breakeven

Vaxart, Inc. to Report Fiscal Year 2024 Results on Mar 20, 2025

Vaxart, Inc. Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Lacklustre Performance Is Driving Vaxart, Inc.'s (NASDAQ:VXRT) 36% Price Drop

Vaxart, Inc. Enters into Modification No. 5 (The “Modification”) to the ATI-RRPV Project Award Agreement

Vaxart, Inc. Announces Board and Committee Changes

New major risk - Shareholder dilution

Vaxart Highlights Progress of Covid-19, Norovirus and Influenza Programs

Vaxart Announces Favorable Dsmb Review of Sentinel Cohort from Covid-19 Phase 2B Clinical Trial

Revenues Not Telling The Story For Vaxart, Inc. (NASDAQ:VXRT) After Shares Rise 47%

Vaxart, Inc. Provides Nasdaq Bid Price Non-Compliance Update

New minor risk - Share price stability

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

New major risk - Financial position

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Consensus revenue estimates increase by 113%, EPS downgraded

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Consensus revenue estimates increase by 865%

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Price target increased by 11% to US$5.25

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Now 27% overvalued after recent price rise

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Consensus revenue estimates increase by 57%

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Market cap size

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

New major risk - Revenue and earnings growth

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index

New major risk - Share price stability

Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate

Consensus revenue estimates decrease by 60%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to US$0.77 loss, revenue downgraded

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate